6.84

2.29% -0.16

Aura Biosciences Inc (AURA)

Overview News Price History Option Chain Financials Why AURA Down? Discussions Forecast

Aura Biosciences Inc stock is traded at $6.84, with a volume of 442.81K. It is down -2.29% in the last 24 hours and up +11.76% over the past month. Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Previous Close:

$7.00

Open:

24h Volume:

442.81K

Relative Volume:

0.71

Market Cap:

$707.51M

Revenue:

Net Income/Loss:

$-112.39M

P/E Ratio:

-3.8791

EPS:

-1.7633

Net Cash Flow:

$-91.64M

1W Performance:

-11.63%

1M Performance:

+11.76%

6M Performance:

+34.38%

1Y Performance:

+1.03%

1-Day Range:

$6.64

$7.30

1-Week Range:

$6.64

$7.87

52-Week Range:

$4.73

$9.535

Aura Biosciences Inc Stock (AURA) Company Profile

Name

Aura Biosciences Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(617)500-8864

Address

80 GUEST STREET, BOSTON

Employee

113

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

AURA's Discussions on Twitter

Compare AURA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AURA Aura Biosciences Inc	6.84	707.51M	0	-112.39M	-91.64M	-1.7633
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-26-25	Resumed	Evercore ISI	Outperform
May-28-25	Resumed	H.C. Wainwright	Buy
Jul-25-24	Initiated	H.C. Wainwright	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy
Jul-19-22	Initiated	JMP Securities	Mkt Outperform

View All

Aura Biosciences Inc Stock (AURA) Latest News

Jul 08, 2026

Form 4 Aura Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant - Stock Titan

Jul 08, 2026

Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender - Stock Titan

Jul 08, 2026

Aura Biosciences Announces Appointment of Jer - Moomoo

Jul 08, 2026

Aura Biosciences strengthens board with new independent director - TipRanks

Jul 08, 2026

Aura Biosciences Appoints Jeremy Bender to Board as Bel-Sar Advances Toward Potential Regulatory Approval for Choroidal Melanoma 1 – Minichart - Minichart

Jul 08, 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors - The Manila Times

Jul 08, 2026

Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director - Stock Titan

Jul 08, 2026

Jul 07, 2026

Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock - 富途牛牛

Jul 07, 2026

Jul 05, 2026

The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily

Jul 05, 2026

AURA Q1 2026 Earnings: Wider-than-Expected Loss as Stock Climbs on Pipeline ProgressSpecial Dividend Alert - dars.gov.et

Jul 05, 2026

Jul 03, 2026

More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k - simplywall.st

Jul 03, 2026

Jul 01, 2026

Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan

Jul 01, 2026

Jun 30, 2026